此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH (PERFORMA)

2026年8月26日 更新者：Altimmune, Inc.

A Phase 3, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in Subjects With Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Phase 3, multicenter, multinational, 2-cohort, randomized, double-blind, placebo controlled, parallel-group pivotal study to evaluate the efficacy, safety, and clinical outcomes of pemvidutide treatment in subjects with noncirrhotic (F2 or F3) metabolic dysfunction-associated steatohepatitis (MASH). Participants will be assigned either to Cohort 1 based on screening histologic (liver biopsy) criteria or to Cohort 2 based on non-invasive test criteria.

研究概览

地位

招聘中

条件

干预/治疗

研究类型

介入性

注册 (估计的)

1800

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习联系方式

学习地点

  • 美国
    • Arkansas
      • North Little Rock、Arkansas、美国、72117
        • 招聘中
        • Altimmune Clinical Study Site
    • California
      • Fountain Valley、California、美国、92708
        • 招聘中
        • Altimmune Clinical Study Site
      • Fresno、California、美国、93720
        • 招聘中
        • Altimmune Clinical Study Site
      • Gardena、California、美国、90247
        • 招聘中
        • Altimmune Clinical Study Site
      • Long Beach、California、美国、90815
        • 招聘中
        • Altimmune Clinical Study Site
    • Florida
      • Miami、Florida、美国、33173
        • 招聘中
        • Altimmune Clinical Study Site
      • Ocala、Florida、美国、34471
        • 招聘中
        • Altimmune Clinical Study Site
    • Ohio
      • Springboro、Ohio、美国、45066
        • 招聘中
        • Altimmune Clinical Study Site
      • Westlake、Ohio、美国、44145
        • 招聘中
        • Altimmune Clinical Study Site

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

All subjects:

  • No significant changes in body weight (±5%) and not participating in a structured weight loss program for the 3 months prior to screening (or since the historical biopsy, if applicable)
  • Body mass index (BMI) ≥ 25.0 kg/m2; if Asian, BMI ≥ 23.0 kg/m2
  • Type 2 diabetes (T2D) or at least 2 components of metabolic syndrome
  • Subject agrees to have liver biopsy(ies) as required per protocol

Cohort 1 - Histologic diagnosis of F2/F3 MASH based on liver biopsy during screening or historical biopsy within 6 months before screening

Cohort 2 - Presumed F2/F3 MASH based on noninvasive testing

Exclusion Criteria:

  • Cirrhosis (F4); portal hypertension or hepatic decompensation; acute or chronic liver disease other than MASH; liver function tests (ALT, AST; alkaline phosphatase; total bilirubin; INR; and platelet count) outside of acceptable ranges; positive HBsAg; active hepatitis C
  • Uncontrolled T2D or clinically significant persistent hyperglycemia

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

  • 主要用途：治疗
  • 分配：随机化
  • 介入模型：并行分配
  • 屏蔽：四人间

武器和干预

参与者组/臂
干预/治疗
安慰剂比较：安慰剂
其他：Placebo
Placebo SC Injection
实验性的：Pemvidutide 2.4 mg
药品：Pemvidutide
Pemvidutide SC Injection
实验性的：Pemvidutide 1.8 mg
药品：Pemvidutide
Pemvidutide SC Injection

研究衡量的是什么？

主要结果指标

结果测量
措施说明
大体时间
Clinical Outcome Event
大体时间：Baseline through end of study (approximately Month 60)
Time to first occurrence of any of the following events through the end of the study: Histologic progression to cirrhosis (F4) on liver biopsy; Liver related events; Liver transplantation; or Death due to any cause
Baseline through end of study (approximately Month 60)
Histological Response: MASH resolution
大体时间：Baseline through Week 52
Proportion of subjects achieving MASH resolution (according to NASH Clinical Research Network [CRN] classification) without worsening of fibrosis
Baseline through Week 52
Histological Response: Fibrosis improvement
大体时间：Baseline through Week 52
Proportion of subjects achieving ≥ 1 stage improvement in liver fibrosis according to the NASH CRN fibrosis staging system without worsening of MASH
Baseline through Week 52

次要结果测量

结果测量
大体时间
Histologic Response: Proportion of subjects achieving both MASH resolution (according to NASH CRN classification) without worsening of fibrosis and ≥ 1 stage improvement in liver fibrosis without worsening of MASH
大体时间：Baseline through Week 52
Baseline through Week 52
HistoIndex qFibrosis: Proportion of subjects with at least a 1 stage improvement in qFibrosis
大体时间：Baseline through Week 52
Baseline through Week 52
Anthropometric parameters: Relative (%) change from baseline in body weight (kg)
大体时间：Baseline through End of Study (approximately Month 60)
Baseline through End of Study (approximately Month 60)
Anthropometric parameters: Relative (%) change from baseline in body mass index (BMI; kg/m2)
大体时间：Baseline through End of Study (approximately Month 60)
Baseline through End of Study (approximately Month 60)
Anthropometric parameters: Relative (%) change from baseline in waist circumference (cm)
大体时间：Baseline through End of Study (approximately Month 60)
Baseline through End of Study (approximately Month 60)
Noninvasive Tests of MASH Inflammatory and Fibrotic Activity: Absolute change from baseline in alanine aminotransferase (ALT; U/L)
大体时间：Baseline through End of Study (approximately Month 60)
Baseline through End of Study (approximately Month 60)
Noninvasive Tests of MASH Inflammatory and Fibrotic Activity: Absolute change from baseline in enhanced liver fibrosis (ELF) score
大体时间：Baseline through End of Study (approximately Month 60)
Baseline through End of Study (approximately Month 60)
Noninvasive Tests of MASH Inflammatory and Fibrotic Activity: Relative (%) change from baseline in vibration controlled transient elastography (VCTE; kPa) by Fibroscan
大体时间：Baseline through End of Study (approximately Month 60)
Baseline through End of Study (approximately Month 60)
HRQoL: Change from baseline in core symptoms of MASH on the NASH-CHECK questionnaire.
大体时间：Baseline through End of Study (approximately Month 60)
Baseline through End of Study (approximately Month 60)
HRQoL: Change from baseline in Short-form 36 (SF-36) summary scores.
大体时间：Baseline through End of Study (approximately Month 60)
Baseline through End of Study (approximately Month 60)
HRQoL: Change from baseline in Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis (CLDQ-NASH) domain scores.
大体时间：Baseline through End of Study (approximately Month 60)
Baseline through End of Study (approximately Month 60)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

Altimmune, Inc.

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年7月30日

初级完成 (估计的)

2028年12月1日

研究完成 (估计的)

2032年12月1日

研究注册日期

首次提交

2026年8月14日

首先提交符合 QC 标准的

2026年8月26日

首次发布 (实际的)

2026年8月31日

研究记录更新

最后更新发布 (实际的)

2026年8月31日

上次提交的符合 QC 标准的更新

2026年8月26日

最后验证

2026年8月1日

更多信息

与本研究相关的术语

其他研究编号

  • ALT-801-301

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)？

是的

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

订阅